Foundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics

Key Terms

pharmacogenetic medical

Pharmacogenetic describes how a person’s genes influence their response to a medicine — like tailoring a prescription to fit a person the way a custom suit fits a body. It matters to investors because genetic-driven prescribing can change a drug’s chances of success in trials, shrink or reshape the pool of patients who can use it, and create opportunities for premium pricing or companion tests that affect a product’s commercial value.

pgx medical

Pharmacogenomics (PGx) is the study and use of a person’s genes to predict how they will respond to medicines, guiding which drugs or doses are likely to work best or cause side effects. For investors it matters because PGx can change a drug’s commercial outcome—similar to tailoring a suit to fit one person rather than selling one-size-fits-all clothing—by improving success rates in trials, shaping regulatory pathways, and affecting market size, pricing, and adoption.

chemotherapies medical

Drugs or combinations of drugs used to kill, slow or stop the growth of cancer cells by interfering with their ability to reproduce or survive; they can be delivered by pill, injection or infusion. Investors care because chemotherapy development, approvals, side-effect profiles and treatment demand drive revenue for drug makers, treatment costs for hospitals and insurers, and can affect clinical trial timelines and regulatory risk — similar to how a single popular product can change a company’s sales and reputation.

cyp2c19 medical

CYP2C19 is a human gene that makes an enzyme responsible for breaking down many common drugs in the body; think of it as a chemical processing plant that speeds up or slows the clearance of medicines. Variations in this gene change how well a drug works or whether it causes side effects, so investors watch CYP2C19-related data because it can affect drug labeling, dosing recommendations, market size for companion tests, and the commercial success of therapies.

cyp2c9 medical

CYP2C9 is a liver protein that acts like a chemical cleanup crew for many prescription drugs, breaking them down so the body can use or eliminate them. Variations in CYP2C9 activity can change how fast drugs are cleared, affecting safety, effective dose, and the risk of interactions—factors that influence clinical trial outcomes, regulatory labels, and market adoption of medications. For investors, CYP2C9-related issues can alter a drug’s commercial prospects or create demand for genetic tests and safer alternatives.

cyp2d6 medical

CYP2D6 is a liver enzyme that acts like a chemical processing machine, breaking down many commonly prescribed medicines so they reach safe and effective levels in the body. People inherit different genetic versions that make the enzyme work slowly, normally, or very quickly, which can change a drug’s effectiveness, side effects and dosing requirements—factors that affect clinical trial outcomes, regulatory labels and a drug’s commercial prospects.

dpyd medical

DPYD is the gene that makes the enzyme responsible for breaking down common chemotherapy drugs called fluoropyrimidines; when the enzyme works poorly because of certain genetic variants, patients can experience severe, sometimes life‑threatening toxicity. Investors should care because DPYD testing affects drug labeling, prescribing, and demand for companion diagnostics and safer dosing strategies—similar to a safety check that determines whether a product needs a different instructions or warning label.

g6pd medical

Glucose-6-phosphate dehydrogenase (G6PD) is an enzyme in red blood cells that helps protect them from damage when the body encounters certain drugs, foods, or infections; think of it as a safety valve that prevents cells from breaking down. Investors care because G6PD deficiency—a common inherited condition—affects how patients respond to treatments, can trigger safety warnings, influence drug trial design, regulatory approval, labeling, and market size for diagnostics and therapies.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

New solution helps guide cancer therapy selection and dosing strategies to support safer, more effective patient care

FoundationOne PGx includes genes associated with the metabolism of medicines that have strong clinical evidence and actionable guidelines, including DPYD

BOSTON & EL MONTE, Calif.--(BUSINESS WIRE)-- Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced plans to launch FoundationOne^®PGx, a pharmacogenetic (PGx) offering to identify genetic differences that influence how medicines are metabolized and processed by the body. FoundationOne PGx will be offered in the United States through a partnership with Fulgent Genetics, Inc. (NASDAQ: FLGT) and will be available to order through the Foundation Medicine portal.

Based on their genetics, patients may metabolize medicines more slowly or more rapidly than expected, which can increase the risk of adverse drug reactions and impact treatment effectiveness. PGx testing helps inform how a patient will process certain medications. It may be ordered early in the disease course to help healthcare providers better understand the potential pharmacogenetic effects of therapies and reduce the risk of adverse drug reactions, or later, in advanced disease—particularly when patients are receiving combination regimens, including chemotherapies.

FoundationOne PGx’s current oncology-relevant panel includes genes associated with the metabolism of medicines that have strong clinical evidence and actionable guidelines, including: CYP2C19, CYP2C9, CYP2D6, DPYD, G6PD, NUDT15, TPMT, UGT1A1 and UGT1A4. Genetic variants in these genes can influence patient response to chemotherapies, targeted therapies and supportive care medications commonly used in oncology.

“FoundationOne PGx is an important addition to our portfolio, helping healthcare providers anticipate potential toxicity of medicines, reduced treatment effectiveness, and increased risk of adverse reactions,” said Todd Druley, M.D., Ph.D., Chief Medical Officer at Foundation Medicine. “When combined with our high-quality comprehensive genomic profiling tests, this PGx offering powered by Fulgent can help healthcare providers build a more comprehensive understanding of each patient’s genomic profile to inform treatment decisions throughout their care.”

“We are excited to expand our partnership with Foundation Medicine, and collectively launch this new service aimed at improving patient care in oncology,” said Brandon Perthuis, Chief Commercial Officer at Fulgent. “This is perfect timing with the recent guideline updates and professional society positions signaling a clear shift toward proactive integration of PGx testing into routine oncology care. We look forward to working collaboratively to ensure patients have access to this important testing.”

Foundation Medicine^® and FoundationOne^® are registered trademarks of Foundation Medicine, Inc.

About Foundation Medicine

Foundation Medicine is a global, patient-focused precision medicine company delivering high-quality, transformative diagnostic solutions in cancer and other diseases. We provide tests and solutions to transform care throughout a patient’s experience, from defining a diagnosis to determining the appropriate treatment to ongoing monitoring. We help accelerate the development of new personalized therapies by leveraging our vast knowledge of precision medicine, real world data and AI-powered tools, expanding the information our diagnostic solutions provide to enable improved outcomes for patients. Every day, we are inspired to think differently to transform the lives of people living with cancer and other diseases. For more information, visit us at www.FoundationMedicine.com and follow us on LinkedIn, X, YouTube, Facebook, Instagram and BlueSky.

About FoundationOne^®PGx

FoundationOne^®PGx is designed and customized to detect genetic variations in the following nine (9) genes associated with actionable oncology drug metabolism that are included in either the FDA's pharmacogenetic associations for which the data support therapeutic management recommendations list or other PGx clinical implementation guidelines (CPIC): CYP2C19, CYP2C9, CYP2D6, DPYD, G6PD, NUDT15, TPMT, UGT1A1 and UGT1A4.

About Fulgent

Fulgent is a technology-based company with a well-established laboratory services business and a therapeutic development business. Fulgent’s laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Fulgent’s therapeutic development business is focused on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The Company aims to transform from a diagnostic business into a fully integrated precision medicine company.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260504283827/en/

Media Contact:
Abigail Linehan, 781-534-3210
newsroom@foundationmedicine.com

Source: Foundation Medicine